CannabisNewsWire
CannabisNewsWire

News and publishing service
for cannabis related companies

LimeLight of The week is


InMed Pharmaceuticals Inc.
(NASDAQ: INM)

View The Complete Profile

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the development, manufacture and commercialization of rare cannabinoids for pharmaceutical and consumer health and wellness applications. InMed is a clinical stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab.

In October 2021, InMed announced its acquisition of BayMedica Inc., a private U.S. firm specializing in the manufacture and commercialization of rare cannabinoids for the health and wellness sector. BayMedica, now operating as a subsidiary of InMed, is a revenue-stage biotechnology firm leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa (EB), a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. A Phase 2 clinical trial in EB is currently underway, marking the first time that a CBN-based formulation has advanced to a Phase 2 clinical trial. The study is taking place at 13 sites across eight countries in Europe, with patient screening and treatment currently ongoing.

InMed is also developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

Commercialization

Through BayMedica, InMed commercializes rare cannabinoids cannabichromene (CBC) and cannabicitran (CBT) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. Additionally, commercial scale production of cannabidivarin (CBDV) is underway, with tetrahydrocannabivarin (THCV) production scheduled to commence in the near future. InMed expects to produce over 100kg of CBDV and THCV in the coming months to meet anticipated initial demand.

“We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand,” Shane Johnson, SVP and General Manager of BayMedica, stated in a January news release. “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high quality rare cannabinoids in these sectors.”

Investment Considerations

  • InMed has a world class leadership team with a successful track record of drug development and commercialization.
  • InMed has a solid and expanding intellectual property portfolio with multiple patents filed.
  • The company recently acquired rare cannabinoids manufacturer BayMedica.
  • InMed retains all commercial rights to its IntegraSyn manufacturing system.
  • InMed has commenced a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa.
  • The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029.
View More





Recent Coverage

InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update

September 23, 2022 1:00 PM

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. “In the final quarter of our fiscal 2022, as well as throughout the previous fiscal year, we have made important advancements in our pharmaceutical drug development programs, including expanding our phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa to include adolescents, and initiating a research collaboration agreement to further screen cannabinoid analogs for potential therapeutic uses. As announced on Sept. 8, 2022, we have made the decision to reduce the efforts of our subsidiary, BayMedica, to pursue commercialization of rare cannabinoids in the health and wellness sector,” said InMed CEO Eric A. Adams. “Moving forward, the company is realigning its focus and resources towards advancing our pharmaceutical drug development programs with the aim of achieving important milestones in the coming quarters and year.”

To view the full source article, visit: https://ibn.fm/d7h0w

Receive SMS Text Alerts from CannabisNewsWire

Text "Cannabis" to 844-397-5787

(US Mobile Phones Only)

Featured Event

Alternative Products Expo, Tampa
11/10 - 11/12 – Tampa

In a completely sold-out show, hundreds of exhibitors and thousands of attendees gathered to experience an industry eventv in 2021 where cannabis, hemp, and other alternative products took the spotlight.

Conference Highlights

  • ENDLESS NETWORKING OPPORTUNITIES
  • 10.000+ Attendees Per event
  • 50+ Speakers per event
  • 300+ VENDORS PER EVENT
  • 1,000+ PRODUCTS PER EVENT
View Event


Upcoming Events

  • CannaCon South Richmond Virginia 10/14 - 10/15
  • MJBizCon 2022 Las Vegas 11/15 - 11/18
  • The Cannabis Expo 2022 Johannesburg, South Africa 11/24 - 11/27
View All Events

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.

Stay Informed
We will be posting information about the presenting companies as they take the stage.

See The Latest

Connect With Us
Follow us on social media for the latest news and information from our network of brands and clients.

follow us on twitter  meet on linkedin  like us on facebook

CannabisNewsWire

CannabisNewsWire
303 S Broadway, Denver, CO 80209 (303) 498-7722


Copyright © 2019. All Rights Reserved.